Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer
Conclusion Saracatinib is a novel oral Src kinase inhibitor that was well tolerated but failed to meet its primary endpoint of improvement in 4 month progression-free survival as a single agent in previously treated metastatic colorectal cancer patients.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Drugs & Pharmacology | Investigational New Drugs | Oral Cancer | Radiography | Study | Toxicology